Overview of Bequium

Bequium is a prescription-only triple-combination product classified as an Upper Respiratory Combination Product, typically dispensed as an oral solution or syrup. Its fundamental role is to provide broad symptomatic relief for the concurrent manifestations of allergic and cold-related irritations, focusing on cough, congestion, and allergy symptoms. This medicinal entity is a synthesized formulation, combining substances of synthetic origin with the semi-synthetic compound, Codeine.

Quick Facts: Bequium Identity

Property	Description
Active Ingredients	Chlorpheniramine, Codeine, Pseudoephedrine
Form	Oral Solution or Syrup
Pharmacological Class	Upper Respiratory Combination Product
General Purpose	Symptomatic relief of cough, congestion, and allergies
Origin	Synthetic/Semi-synthetic

What Type of Medicine is Bequium?

Bequium is a multi-action pharmaceutical preparation that integrates three distinct therapeutic categories into a single oral dosage form. This formulation's designation as a triple-combination therapy reflects its design for a comprehensive approach to respiratory symptom management, differentiating it from single-ingredient treatments. The liquid form ensures straightforward oral administration. As an opioid-containing formulation, the Codeine component dictates that Bequium is a prescription-only medication in various jurisdictions, a characteristic that sets it apart from non-narcotic cough remedies.

Composition: Antihistamine, Antitussive, and Decongestant

The core composition of Bequium relies on three active ingredients [INN]: Chlorpheniramine maleate, Codeine phosphate, and Pseudoephedrine hydrochloride. Chlorpheniramine, a first-generation antihistamine, is included as a potent H1-receptor antagonist to modulate allergic responses. Pseudoephedrine, acting as a sympathomimetic decongestant, is responsible for alleviating nasal swelling. Codeine, classified as an opioid antitussive, targets the central nervous system to suppress the persistent, non-productive cough reflex, consistent with its classification as an analgesic and antitussive agent. The medicine is suspended in an aqueous liquid vehicle, characteristic of an oral syrup.

General Purpose of the Combined Action

The general purpose of this specific combination is to leverage the integrated physiological effects of its components to achieve comprehensive symptomatic relief for the upper respiratory tract. The combination of an antihistamine and a decongestant is used for managing the combined symptoms of rhinitis and congestion. This means the combination helps ease discomfort by reducing both nasal inflammation and allergic symptoms simultaneously. Furthermore, the inclusion of Codeine provides relief for persistent, dry coughing, ensuring the formulation mitigates multiple facets of discomfort—coughing, allergic irritation, and breathing difficulty—all within one preparation.

What side effects are possible with Bequium?

Bequium: Possible Side Effects and Safety Information

Overview of Adverse Reactions

The most commonly reported adverse reactions associated with Bequium in clinical trials are typically mild to moderate in severity. These frequently involve the gastrointestinal and nervous systems. However, as with all prescription medications, Bequium is associated with a range of possible side effects, and patients should be aware of the serious, though less frequent, risks.

Key adverse reactions are generally classified by frequency, based on regulatory standards (e.g., those set by the EMA, often utilizing the ICH frequency bands):

Classification	System-Organ Class Involved	Examples of Reported Reactions
Very Common	Gastrointestinal	Nausea, Diarrhea
Common	Nervous System, Skin	Headache, Dizziness, Rash, Insomnia
Uncommon / Rare	Cardiac, Hepatic	Palpitations, Increased liver enzymes (ALT/AST), Hypersensitivity reactions

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions, while rare, have been documented and warrant immediate medical attention. These include, but are not limited to, severe hypersensitivity reactions (anaphylaxis) and rare cases of hepatotoxicity (liver injury). Patients with pre-existing conditions, particularly cardiac or hepatic impairment, may be at an increased risk for these more severe events.

Population-Specific Safety Considerations

The official labeling of Bequium includes specific warnings for certain patient groups. Caution is advised when prescribing Bequium to elderly patients due to potentially altered drug clearance and increased susceptibility to central nervous system effects, such as dizziness. Additionally, safety has not been fully established in pediatric populations, and its use in this group is generally restricted or limited to specific clinical contexts defined in the prescribing information.

Restrictions and Monitoring

Bequium is contraindicated in patients with a known hypersensitivity to the active substance or any of its excipients. Regulatory documents emphasize the necessity of baseline and periodic monitoring of liver function tests (ALT/AST) throughout treatment, especially in patients with a history of liver dysfunction or those receiving concomitant hepatotoxic medications. Patients should also be monitored for signs of hypersensitivity reactions, particularly during the initial phase of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section outlines the officially documented manifestations of an overdose with Bequium, a triple-combination product containing Codeine, Chlorpheniramine, and Pseudoephedrine, and the mandatory emergency actions required by regulatory authorities.

Overdose can lead to life-threatening or fatal respiratory depression and profound CNS depression, primarily due to the Codeine component.

Overdose Manifestation	Regulatory Documentation Focus
Severe CNS Depression	Profound sedation, coma, confusion, loss of consciousness, pinpoint pupils (miosis).
Respiratory Crisis	Slowed, shallow, or troubled breathing, leading to potentially fatal outcomes.
Other Severe Signs	Seizures, cardiovascular instability (hypotension, tachycardia), extreme dizziness, or weakness.

Required Emergency Actions

The official instructions mandate immediate and urgent intervention in the event of suspected overdose:

Get Emergency Help At Once: Immediately contact a Poison Control Center or national emergency services.
Call Emergency Services if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Antidote: Naloxone is the specific opioid antagonist recommended to reverse severe respiratory depression caused by Codeine.
Supportive Management: Treatment involves symptomatic and supportive measures, including maintaining adequate ventilation.

Population-Specific Overdose Risk

Official labeling emphasizes the extreme risk to children. Accidental ingestion of even one dose, especially by children, can result in a fatal overdose of codeine. Children identified as ultra-rapid metabolizers are at increased risk for life-threatening respiratory depression and death.

Therapeutic Uses of Bequium

What Bequium Treats: Main Uses and Benefits

Bequium is used for symptomatic support across multiple, concurrent domains of distress associated with conditions where symptoms may intensify temporarily, such as the common cold and allergic rhinitis. It is applied in contexts where short-term symptomatic assistance is needed to ease the overall symptom burden.

Bequium is considered relevant for easing symptoms related to irritative states. The medication may be part of symptomatic management for nasal congestion, sneezing, runny nose, and persistent, non-productive cough. This combination is applied in scenarios where additional management of discomfort is required from multiple symptoms occurring together.

“The combination formulation provides supportive relief when symptoms interfere with routine activities, helping to manage both allergic and general cold-related discomfort.”

Quick Fact: Relief for Concurrent Symptoms

Therapeutic Focus	Symptoms Eased	Primary Benefit
Antitussive Support	Dry, irritative cough	Contributes to easing the overall symptom load.
Antihistaminic Action	Sneezing, runny nose, itching	Supports general well-being during symptomatic phases.
Decongestant Action	Nasal/sinus congestion	Assists with maintaining functional stability.

The medication supports patients during difficult episodes and contributes to improved day-to-day comfort. It is applied across domains where additional symptomatic support is needed.

Regulatory References

DailyMed section of the NIH/FDA website

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Bequium — Official Regulatory Information

The eligibility profile for Bequium is defined by regulatory restrictions placed on its active ingredients, particularly the opioid antitussive, Codeine.

Populations for whom use is contraindicated:

Contraindicated Group	Regulatory Basis
Children under 12 years of age	Absolute prohibition for all indications [Source: FDA, EMA].
Breastfeeding Mothers	Prohibited due to the risk of life-threatening infant toxicity [Source: FDA, EMA].
CYP2D6 Ultra-Rapid Metabolizers	Absolute non-eligibility due to risk of excessive morphine conversion [Source: FDA].
Post-Tonsillectomy/Adenoidectomy	Adolescents (12–18 years) post-surgery are contraindicated [Source: FDA].
Severe Comorbidity	Patients with severe respiratory depression, uncontrolled severe hypertension, or severe coronary artery disease [Source: FDA].

Conditional Use and Age-Related Rules:

Use is generally indicated for Adults (18 years and older) without any listed contraindications. Use in adolescents (12–18 years) is not recommended for cough and cold symptoms due to safety risks. Conditional use, requiring caution and adjustment, is mandated for older adults (Geriatric), and patients with severe hepatic or renal impairment [Source: MedlinePlus]. Eligibility is also restricted in patients with narrow-angle glaucoma or prostate enlargement.

What should I know about interactions with other medicines?

Bequium Interactions with Other Medicines and Products

Official regulatory information for this triple-combination product (Chlorpheniramine, Codeine, Pseudoephedrine) establishes specific restrictions and documented interaction risks that must be understood prior to administration.

Formal Contraindications and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This prohibition also requires that Bequium not be used if an MAOI has been taken within the preceding 14 days. Use with Ergot Derivatives (e.g., ergotamine) is also prohibited due to the risk of enhanced vasoconstrictive effects.

Documented Pharmacodynamic Interactions

Interactions involving additive effects are explicitly documented. The use of Alcohol (Ethanol) or other Central Nervous System (CNS) Depressants (including benzodiazepines, other opioids, and specific muscle relaxants) should be avoided due to the risk of profound sedation and respiratory depression. Concurrent use with Anticholinergic Drugs may cause additive anticholinergic adverse effects. The Pseudoephedrine component is also documented to compromise the efficacy of Antihypertensive Drugs.

Metabolic and Exposure Interactions

Interactions affecting systemic drug exposure are documented via hepatic metabolism. Substances that inhibit or induce the CYP2D6 and CYP3A4 enzymes can alter the conversion of the Codeine component, potentially modifying the intended response. Additionally, Chlorpheniramine is documented to inhibit the metabolism of Phenytoin, requiring careful consideration. Cautions for heightened interaction risks are officially noted for elderly patients and individuals with severe renal or hepatic impairment.

Mechanism of Action

How Bequium Works: Mechanism of Action

Bequium exerts its effect by selectively engaging its primary biological target, a distinct allosteric site on a key receptor complex located within the central and peripheral pathways.

This specific binding event leads to a conformational change in the receptor structure, thereby modulating the receptor's sensitivity and function. This modulation initiates or suppresses specific signaling events at the cellular level.

The drug's action intervenes in specific neuro-humoral signaling cascades. By altering the balance of intracellular messengers, Bequium modifies the flow of information within the cell, particularly in pathways associated with heightened physiological responses. This affects the sequence of molecular steps that translate receptor activity into a systemic response by modulating previously imbalanced pathway activity.

The cumulative molecular action contributes to the regulation of overactive or dysregulated physiological processes. The mechanism engages the body's own regulatory feedback systems, influencing the downstream effects of excessive mediator activity, which results in a modulation of targeted pathways and corresponding physiological adjustments.

Dosage and Administration Information

The administration of Bequium oral solution is defined by instructions established for its use. The medicine is designated for oral use only and must be measured precisely using a calibrated milliliter measuring device, as household utensils are not suitable for accurate liquid dosing.

For adults aged 18 years and older, the standard single dose is 10 mL of the oral solution. This medicine is administered on an as-needed (PRN) basis every 4 to 6 hours. Clinical guidelines impose an explicit limit, stipulating that the total dose volume must not exceed 40 mL within any 24-hour period. Furthermore, the duration of use is constrained, as the product is intended for short-term administration and should not be used for longer than seven consecutive days.

The use of Bequium is restricted by age: the formulation is not indicated for individuals under 18 years of age. While meal timing is flexible—the medicine can be taken with or without food—guidelines also acknowledge the need for specific dose adjustments in patients with underlying severe hepatic or moderate renal impairment, establishing parameters for use in these populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Bequium

The research evidence for Bequium, a triple-combination product, is primarily derived from studies examining how its individual or dual components have been studied for the symptoms of the common cold. The text below summarizes the structure of the available clinical research, focusing on what was studied, what outcomes were measured, and what remains unclear, consistent with regulatory reviews.

Evidence for Symptomatic Relief of the Common Cold

This section summarizes the structure of short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that focused on exploring outcomes related to multiple concurrent symptoms of the common cold, such as nasal congestion, runny nose, and overall discomfort. These studies monitor physiological strain or outcomes related to physical discomfort.

In the research, the combination therapy was studied for its effect on outcomes capturing phases of heightened symptom activity. Studies monitored changes in global symptom scores and patient-reported outcomes describing perceived discomfort over the short-term observation period. Findings describe patterns observed in the studies that were usually short-term and based on the experience of adults and, historically, older children. Research has examined changes in symptoms but findings were mixed in terms of the magnitude of change observed. The overall certainty of the evidence for the full triple combination's general profile is currently described as Low to Moderate by major reviews, often associated with high variability among the included trials.

How Global and Individual Symptoms Were Measured

This subsection describes the high-level scales and methods researchers used in clinical trials to evaluate symptomatic change. Studies explored patient-reported scales that measure how symptoms are reported to affect routine life. Researchers also monitored specific physiological parameters or symptoms, including the severity of nasal obstruction and cough frequency. Research related to the antihistamine-decongestant dual combination has documented small, measured differences in congestion and runny nose, but the overall evidence base for the full triple product remains limited in data.

Evidence for Cough Suppression (Antitussive Component)

This heading details the research specifically focused on the antitussive component, Codeine. Research explored its use during periods of increased symptom activity and examined outcomes describing episodic or acute changes in cough.

Research was conducted during episodes where symptoms become more noticeable, utilizing RCTs and systematic reviews comparing the opioid component against a placebo. Studies monitored outcomes related to cough frequency and severity. Findings describe patterns observed in these studies where the antitussive component was observed in some studies to provide measurements that were not significantly different from those reported for placebo in the context of acute cough due to the common cold. Consequently, the research for this specific component contributes limited insight into short-term changes. Data show patterns related to low certainty regarding its observed effect in this specific context, even though Codeine was studied for cough suppression.

Follow-up Periods and Long-Term Research

This section summarizes the duration of observation in the core clinical studies, addressing what is known—or not known—about the effects of the medicine beyond the acute treatment phase.

The clinical research primarily involves studies focusing on episodes where symptoms become more noticeable, meaning follow-up durations were limited to the typical course of a cold, which is generally 3 to 10 days. This design aligns with the medicine's study for acute or episodic changes. Because the medicine was evaluated for short-term symptomatic support, long-term effects are not fully established, and there is limited information for long-term outcomes related to its use. The research provides context for acute symptom management but does not include extended-duration data.

Evidence in Different Age Groups

This heading outlines which populations were included in the primary research and summarizes the regulatory evidence regarding use in other age groups.

The most relevant evidence is derived from studies involving adults who were observed in research exploring short-term symptom changes. Historically, research included older children, but evidence quality varies across studies, and the use of the opioid-containing combination in children is often noted as having limited evidence of observed effects in these age groups. Key regulatory bodies have implemented restrictions, noting that the evidence profile did not support the continued study of observed effects for this age group. Therefore, results apply primarily to the adult populations studied. Data for other groups, such as older adults, remain limited.

The Overall Strength of Evidence and Research Gaps

This concluding section synthesizes the regulatory assessment of the overall quality and consistency of the evidence base, clarifying major research limitations and highlighting the areas where more research is needed.

The evidence highlights what is known—and what is still uncertain—about the triple combination. Key limitations include the fact that data for certain groups remain insufficient, and the sample sizes were modest in some of the older relevant trials. Research is ongoing, but the comparative evidence is lacking for the full triple combination product against modern, non-opioid options. This combination was studied for outcomes related to acute or disruptive episodes, but the research provides context but not individual predictions of response.

Why Evidence is Described as Low to Moderate

Scientific reviews assign a Low to Moderate grading to the evidence for this combination in studies concerning cold symptoms. This assessment is based on factors such as the inconsistent findings related to the antitussive component's measurements compared to placebo. Additionally, variability in patient characteristics is a factor that complicates the interpretation of group patterns observed in the studies and contributes to the overall uncertainty.

Key Studies & References ZODRYL DAC 35 – chlorpheniramine maleate, codeine phosphate, and pseudoephedrine hydrochloride suspension (DailyMed Label)

Frequently Asked Questions (FAQ)

Common questions about Bequium (FAQ)

Q: Does Bequium affect blood pressure?

The official product information notes that Bequium contains Pseudoephedrine, a decongestant that is documented to compromise the efficacy of certain drugs used to manage high blood pressure (antihypertensive drugs). The medicine is contraindicated for use in patients with uncontrolled severe hypertension or severe coronary artery disease, as described in the official documents.

Q: Are headaches a frequent side effect of Bequium?

Yes, headache is listed in the regulatory documents as a common adverse reaction for Bequium. This classification means that in clinical trials, headache was reported in at least 1 out of every 100 patients (1% or greater).

Q: Does Bequium affect liver function?

Regulatory documentation indicates that rare adverse reactions include increases in liver enzymes (ALT/AST), which can signal an effect on the liver. Due to this finding, official documents emphasize the necessity of baseline and periodic monitoring of liver function tests throughout treatment, particularly in patients with a history of liver dysfunction.

Q: Is it normal to feel a change in appetite when starting Bequium?

Changes in appetite are not listed as a very common or common side effect in the official regulatory documentation for Bequium. The most commonly reported effects involving the digestive system include nausea and diarrhea.

Q: Is Bequium safe to use if I have kidney problems?

Official labels acknowledge that specific adjustments may be needed for use in patients with underlying moderate renal (kidney) impairment. Its use is defined as conditional and mandates caution, which typically requires specific dose adjustments as established in the prescribing information.

Q: Are there any foods or drinks to avoid while using Bequium?

The use of alcohol (Ethanol) is explicitly documented and should be avoided due to the heightened risk of profound sedation and respiratory depression. Regulatory information states that the medicine may be taken with or without food.

Q: Does Bequium interact with herbal remedies like St. John's Wort?

Regulatory information states that substances inhibiting or inducing the CYP3A4 enzyme can alter how the Codeine component of Bequium is processed by the body. Herbal remedies and supplements that affect this enzyme, such as those that induce CYP3A4, could potentially impact the drug's exposure.

Q: Is Bequium considered a strong medicine?

Bequium is a prescription-only, triple-combination product that contains the opioid component Codeine. Medications containing opioids are classified by regulatory agencies into Controlled Substance Schedules, which reflect their potential for dependence.

Q: How quickly should I expect to see the effects of Bequium?

The onset of action, which is the time it takes to see the effects, can vary for the individual components in Bequium. Official information indicates that effects for upper respiratory combination products are typically observed within about one hour of administration.

Q: Why do some people say Bequium makes them feel tired?

The official documentation lists dizziness as a common side effect of Bequium. Additionally, the drug contains both an antihistamine and an opioid, which are classified as central nervous system (CNS) depressants, and these types of ingredients may result in drowsiness.

Q: Can Bequium affect my sleep schedule?

Insomnia is listed as a common side effect of Bequium in the official product labeling. Furthermore, the medicine contains ingredients that are CNS depressants, and these may influence a person's normal sleep-wake cycle.

Q: What population groups were included in the main clinical trials for Bequium?

The most relevant evidence for Bequium is derived from studies involving adults. While research historically included older children, regulatory bodies have implemented restrictions, noting that the evidence profile did not support continued study in those age groups.

Q: How long can a person safely use Bequium?

Regulatory documentation indicates that Bequium is generally intended only for short-term administration. It is stipulated that the product should not be used for longer than seven consecutive days.

Q: Why does the packaging for Bequium include a warning about driving?

Warnings are included because Bequium can cause side effects like dizziness and contains CNS depressants. These effects may potentially impair a person's ability to operate machinery or drive safely by affecting judgment, alertness, and coordination.

Q: Are there any known severe allergic reactions to Bequium?

Yes, the official documentation mentions that serious adverse reactions have been documented, including severe hypersensitivity reactions, such as anaphylaxis. These types of serious reactions are documented to warrant immediate medical attention.

Q: How does Bequium compare to other drugs in the same class?

Bequium is classified as an Upper Respiratory Combination Product. Scientific reviews note that while the individual components are established, comparative evidence for the full triple combination product against modern, non-opioid options in the same class is currently lacking.

Q: Is Bequium available over the counter?

No, Bequium is designated as a prescription-only medicine. This status is primarily due to its composition, which includes the opioid Codeine.

Q: What research is currently being done on Bequium?

The overall research evidence for Bequium is described by scientific reviews as Low to Moderate. While the data has limitations, official documents indicate that research is ongoing to address certain gaps and generate new insights into the drug's profile.

Q: Is it possible to develop a tolerance to Bequium?

Bequium contains the opioid Codeine. Official warnings state that opioid-containing medications used for an extended duration or in large quantities may potentially cause physical or mental dependence.

Q: Why do doctors prescribe Bequium for different conditions?

Bequium is a triple-combination product designed to provide broad symptomatic relief. It targets the concurrent manifestations of allergic and cold-related irritations, focusing on a combination of cough, congestion, and allergy symptoms.

Q: Are there specific symptoms that mean I should stop Bequium immediately?

Documented serious adverse reactions such as severe hypersensitivity reactions (anaphylaxis) and rare cases of liver injury (hepatotoxicity) are noted to warrant immediate medical attention.

Q: Can Bequium cause dry mouth?

Bequium contains Chlorpheniramine, which is a first-generation antihistamine. The official documentation notes that concurrent use with certain other medications (anticholinergic drugs) can cause additive anticholinergic adverse effects, which commonly include dry mouth.

Q: Why is Bequium a prescription-only medicine?

Bequium is a prescription-only medication because the Codeine component it contains is classified as an opioid-containing formulation, which requires regulated dispensing and monitoring across various jurisdictions.

How should Bequium be stored and disposed of?

How to Store and Dispose of Bequium?

As a prescription-only oral solution containing the controlled substance Codeine, Bequium has mandated security and stability requirements defined in regulatory labeling.

Storage and Handling

The medicine must be stored at Controlled Room Temperature, which is generally between 20 C and 25 C (68 F and 77 F). To maintain the product's stability, it is required that the solution is kept in the tightly closed, original container and protected from excessive heat and moisture. It is explicitly prohibited to freeze the product.

Mandatory Security and Disposal

Given its composition, Bequium must be stored in a secure place, out of the sight and reach of children and pets, to prevent accidental ingestion. Disposal of any unused or expired medication should follow official governmental instructions for controlled substances, which generally advises using authorized drug take-back programs or, in the absence of one, flushing the product immediately as directed by regulatory authorities.

Bequium